J&J Marketed Risperdal for Kids After FDA Warnings, Jurors Told

The antipsychotic drug Risperdal was marketed for children and adolescents by Johnson & Johnson’s Janssen unit after warnings by the U.S. Food and Drug Administration not to do so, a witness told jurors.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.